Genipin is a natural compound isolated from the fruit of Gardenia jasminoides with various pharmacological effects. In this study, we investigated whether
genipin effectively alleviates allergic responses in a murine model of
ovalbumin (OVA)-induced
asthma. The mice were administered an
intraperitoneal injection of OVA on day 0 and 14 to boost the immune response;
genipin was then administered from day 18 to 23 by oral gavage. On days 21 to 23, mice were OVA-challenged using am ultrasonic
nebulizer, and
airway hyperresponsiveness (AHR) was determined on day 24 by plethysmography.
Genipin significantly reduced the inflammatory cell count in bronchoalveolar lavage fluids (BALF) and AHR, which were accompanied by lower
interleukin-5 (IL-5),
IL-13 and OVA-specific
immunoglobulin (Ig) E levels in the BALF or serum from OVA-induced asthmatic mice. In histology,
genipin significantly decreased airway
inflammation and mucus hypersecretion in OVA-induced asthmatic mice. Additionally,
genipin inhibited OVA-induced increases in the expression of
inducible nitric oxide synthase and
cyclooxygenase-2 proteins. Further,
genipin reduced the activity and
protein levels of
matrix metalloproteinase-9 in lung tissue from OVA induced asthmatic mice. Overall,
genipin effectively alleviated the asthmatic inflammatory response in an OVA-induced asthmatic model. Therefore, our results suggest that
genipin has therapeutic potential for treating
asthma.